Garçon N - Search Results

1

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N. Didierlaurent AM, et al. Among authors: garcon n. J Immunol. 2009 Nov 15;183(10):6186-97. doi: 10.4049/jimmunol.0901474. Epub 2009 Oct 28. J Immunol. 2009. PMID: 19864596

2

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M. Morel S, et al. Among authors: garcon n. Vaccine. 2011 Mar 16;29(13):2461-73. doi: 10.1016/j.vaccine.2011.01.011. Epub 2011 Jan 20. Vaccine. 2011. PMID: 21256188

3

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.

Garçon N, Wettendorff M, Van Mechelen M. Garçon N, et al. Expert Opin Biol Ther. 2011 May;11(5):667-77. doi: 10.1517/14712598.2011.573624. Epub 2011 Apr 4. Expert Opin Biol Ther. 2011. PMID: 21457083 Review.

4

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.

Garçon N, Van Mechelen M. Garçon N, et al. Expert Rev Vaccines. 2011 Apr;10(4):471-86. doi: 10.1586/erv.11.29. Expert Rev Vaccines. 2011. PMID: 21506645 Review.

5

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.

Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M. Garçon N, et al. BioDrugs. 2011 Aug 1;25(4):217-26. doi: 10.2165/11591760-000000000-00000. BioDrugs. 2011. PMID: 21815697 Review.

6

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.

Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, Garçon N, Van Mechelen M, Morel S. Didierlaurent AM, et al. Among authors: garcon n. J Immunol. 2014 Aug 15;193(4):1920-30. doi: 10.4049/jimmunol.1400948. Epub 2014 Jul 14. J Immunol. 2014. PMID: 25024381

7

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Garçon N, Chomez P, Van Mechelen M. Garçon N, et al. Expert Rev Vaccines. 2007 Oct;6(5):723-39. doi: 10.1586/14760584.6.5.723. Expert Rev Vaccines. 2007. PMID: 17931153 Review.

8

The safety evaluation of adjuvants during vaccine development: the AS04 experience.

Garçon N, Segal L, Tavares F, Van Mechelen M. Garçon N, et al. Vaccine. 2011 Jun 15;29(27):4453-9. doi: 10.1016/j.vaccine.2011.04.046. Epub 2011 Apr 27. Vaccine. 2011. PMID: 21527299 Review.

9

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Garçon N, Vaughn DW, Didierlaurent AM. Garçon N, et al. Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. Expert Rev Vaccines. 2012. PMID: 22380826 Review.

10

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G. Vandepapelière P, et al. Among authors: garcon n. Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page